Heir to the throne or young pretender: can targeted therapy added to gemcitabine-cisplatin doublet therapy improve outcomes for advanced urothelial cancer?

Eur Urol. 2015 Apr;67(4):603-4. doi: 10.1016/j.eururo.2014.12.023. Epub 2014 Dec 24.

Author

Alison Birtle¹

Affiliation

¹ Rosemere Cancer Centre Royal Preston Hospital, Preston, Lancashire, UK. Electronic address: Alison.birtle@lthtr.nhs.

PMID: 25542626
DOI: 10.1016/j.eururo.2014.12.023

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / toxicity*
Bone Marrow Diseases / chemically induced*
Cisplatin / therapeutic use*
Deoxycytidine / analogs & derivatives*
Female
Humans
Indoles / toxicity*
Male
Pyrroles / toxicity*
Urologic Neoplasms / drug therapy*

Substances

Indoles
Pyrroles
Deoxycytidine
Cisplatin